NEW YORK (GenomeWeb) – PreCyte has received a one-year, $300,000 grant from the National Cancer Institute to develop a blood-based lung cancer diagnostic based on its core Indicator Cell Assay Platform (ICAP) technology.

ICAP was originally developed at the Institute for Systems Biology in the lab of company Co-founder John Aitchison and involves the use of cultured cells as biosensors, exposing them to patient serum and analyzing the transcriptional effect.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.